Working... Menu

ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01098435
Recruitment Status : Completed
First Posted : April 2, 2010
Last Update Posted : August 23, 2011
Information provided by (Responsible Party):
Alkermes, Inc.

Brief Summary:
The purpose of this study is to evaluate the safety of daily doses of RDC-0313 (ALKS 33) compared with placebo in adults with binge-eating disorder (BED). An additional objective is to explore the efficacy of RDC-0313 treatment in comparison with placebo in adults with binge-eating disorder.

Condition or disease Intervention/treatment Phase
Binge Eating Disorder Drug: RDC-0313 (ALKS 33) Drug: Placebo Phase 2

Detailed Description:
Following screening, eligible subjects will be randomized in a 1:1 ratio to RDC-0313 (ALKS 33) or matching placebo. Once-daily at-home dosing will begin at randomization and will continue for 6 weeks. There will be 8 study visits over a 12-week study period. On an ongoing basis, subjects will complete a take-home binge diary designed to record the number of binge-eating episodes (binge episodes) and binge-eating days (binge days, days during which at least 1 binge occurred), as well as snacks and meals consumed daily over each 7-day period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Pilot Study of the Safety and Efficacy of RDC-0313 in Adults With Binge Eating Disorder
Study Start Date : May 2010
Actual Primary Completion Date : May 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eating Disorders

Arm Intervention/treatment
Experimental: RDC-0313 (ALKS 33)
2-capsules taken orally
Drug: RDC-0313 (ALKS 33)
Capsules for daily oral administration

Placebo Comparator: Placebo
2-capsules taken orally
Drug: Placebo
Capsules containing lactose and no active drug for daily oral administration

Primary Outcome Measures :
  1. Number of participants in each dose group reporting at least 1 treatment-emergent adverse event (TEAE) [ Time Frame: 6 Weeks ]
    A TEAE is any adverse event (AE), regardless of causality, that either: begins after a participant's first dose of study drug, up to and including the final follow-up visit; or started before a participant's first dose of study drug but worsens in severity after the first dose of study drug, up to and including the final follow-up visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meet the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, text revised (DSM-IV-TR) criteria for a diagnosis of binge eating disorder (BED)
  • Display greater than or equal to 3 binge eating days per week
  • Body mass index (BMI) greater than or equal to 30 kg/m2
  • Age of 18 years or older
  • Women of childbearing potential must agree to use an approved method of birth control for the duration of the study

Exclusion Criteria:

  • Concurrent symptoms of bulimia nervosa or anorexia nervosa
  • Suicidal ideation
  • DSM-IV-TR diagnosis of substance abuse or dependence (except nicotine or caffeine) within 6 months prior to randomization
  • Positive urine toxicological screen for benzodiazepines, opioids, amphetamine/methamphetamine, or cocaine at screening or randomization
  • Women who are pregnant or breastfeeding
  • Participation in a psychological or weight loss intervention for BED that was initiated within the 3 months prior to screening
  • Clinically unstable medical disease
  • History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
  • History of seizures, including clinically significant febrile seizures in childhood
  • Current or anticipated need for prescribed opioid medication during the study period
  • Use of any psychotropic medications (other than hypnotics)
  • Participation in a clinical trial of a pharmacological agent within 30 days prior to screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01098435

Layout table for location information
United States, Arizona
Alkermes' Investigational Study Site
Tucson, Arizona, United States, 85712
United States, Minnesota
Alkermes' Investigational Study Site
Minneapolis, Minnesota, United States, 55454
United States, New York
Alkermes' Investigational Study Site
Manlius, New York, United States, 13104
United States, North Carolina
Alkermes' Investigational Study Site
Raleigh, North Carolina, United States, 27612
United States, Ohio
Alkermes' Investigational Study Site
Mason, Ohio, United States, 45040
Alkermes' Investigational Study Site
Toledo, Ohio, United States, 43623
Sponsors and Collaborators
Alkermes, Inc.
Layout table for investigator information
Study Director: Marc deSomer, MD Alkermes, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alkermes, Inc. Identifier: NCT01098435     History of Changes
Other Study ID Numbers: ALK33-101
First Posted: April 2, 2010    Key Record Dates
Last Update Posted: August 23, 2011
Last Verified: August 2011

Keywords provided by Alkermes, Inc.:
Binge eating disorder

Additional relevant MeSH terms:
Layout table for MeSH terms
Feeding and Eating Disorders
Binge-Eating Disorder
Mental Disorders
Pathologic Processes
Signs and Symptoms, Digestive
Signs and Symptoms
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents